Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15a1f58e176ed86ee706545002dd4649 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e52d326080d9aabcbf9e0613b3e5357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f231b876962d9de6a9f52d7a45540c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6ae224073fa9ba2acc22ba3a80c75b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8281ac9f4fb11f15a5da018344453338 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0812 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea21fa9a29416cc11c137974f84b9c5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc26d770055d5da2238f759bc41c696 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_534dd513d7f306a0d6dadb3dec5116b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_553081e2b89b1560c730f2c17c886967 |
publicationDate |
2012-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8222203-B2 |
titleOfInvention |
Macrocyclic oximyl hepatitis C serine protease inhibitors |
abstract |
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: n nwhich inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention. |
priorityDate |
2007-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |